AAV-mediated delivery of therapeutic antibodies to the inner ear
US11697801B2 · kind B2 · utility
3Cited by
48References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 3, 2021 |
| Grant date | Jul 11, 2023 |
| Priority date | — |
| Expiry date | Aug 3, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.